抗うつ薬のグローバル市場(2023~2028):選択的セロトニン再取り込み阻害薬(SSRI)、セロトニン・ノルアドレナリン再取り込み阻害薬(SNRI)、三環系抗うつ薬(TCA)、モノアミン酸化酵素阻害薬(MAOI)、その他

【英語タイトル】Antidepressant Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Mordor Intelligenceが出版した調査資料(MOR23MH106)・商品コード:MOR23MH106
・発行会社(調査会社):Mordor Intelligence
・発行日:2023年1月23日
・ページ数:120
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後2-3営業日)
・調査対象地域:アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,750 ⇒換算¥703,000見積依頼/購入/質問フォーム
Corporate License(複数拠点内で共有可)USD8,750 ⇒換算¥1,295,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Mordor Intelligence社の市場調査書によると、世界の抗うつ薬市場規模が、予測期間中、CAGR 3.5%で増加すると推測されています。本書では、抗うつ薬の世界市場について広く調査・分析を行い、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別(選択的セロトニン再取り込み阻害薬(SSRI)、セロトニン・ノルアドレナリン再取り込み阻害薬(SNRI)、三環系抗うつ薬(TCA)、モノアミン酸化酵素阻害薬(MAOI)、その他)分析、うつ病性障害別(大うつ病性障害、強迫性障害(OCD)、全般性不安障害(GAD)、パニック障害(PD)、その他)分析、地域別(アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン)分析、競争状況、市場機会・将来動向などの項目について記載しています。並びに、本書に記載されている企業情報には、AbbiVe Inc.、AstraZeneca、Eli Lilly and Company、GlaxoSmithKline PLC、Johnson & Johnson、H. Lundbeck ASなどが含まれています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・市場動向
・世界の抗うつ薬市場規模:製品別
- 選択的セロトニン再取り込み阻害薬(SSRI)の市場規模
- セロトニン・ノルアドレナリン再取り込み阻害薬(SNRI)の市場規模
- 三環系抗うつ薬(TCA)の市場規模
- モノアミン酸化酵素阻害薬(MAOI)の市場規模
- その他抗うつ薬の市場規模
・世界の抗うつ薬市場規模:うつ病性障害別
- 大うつ病性障害における市場規模
- 強迫性障害(OCD)における市場規模
- 全般性不安障害(GAD)における市場規模
- パニック障害(PD)における市場規模
- その他うつ病性障害における市場規模
・世界の抗うつ薬市場規模:地域別
- 北米の抗うつ薬市場規模
アメリカの抗うつ薬市場規模
カナダの抗うつ薬市場規模
メキシコの抗うつ薬市場規模

- ヨーロッパの抗うつ薬市場規模
ドイツの抗うつ薬市場規模
イギリスの抗うつ薬市場規模
フランスの抗うつ薬市場規模

- アジア太平洋の抗うつ薬市場規模
中国の抗うつ薬市場規模
日本の抗うつ薬市場規模
インドの抗うつ薬市場規模

- 南米/中東の抗うつ薬市場規模
ブラジルの抗うつ薬市場規模
アルゼンチンの抗うつ薬市場規模
サウジアラビアの抗うつ薬市場規模
・競争状況
・市場機会・将来動向

The antidepressant market is expected to register a CAGR of 3.5% over the forecast period.

The pandemic has long and short-term impacts on the individual’s mental illness, given the hurdles faced during the crisis, such as social isolation due to lockdown, job insecurity, and fear of being infected by the coronavirus. Hence, many researchers researched to find an effective treatment for the disease. For instance, as per the January 2022 research article, several shreds of evidence showed the potential therapeutic role of fluvoxamine for COVID-19. Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) approved for treating obsessive-compulsive disorder. Moreover, a 2021 research study result demonstrated when participants were randomly assigned to fluvoxamine (Luvox, Abbott) at a dose of 100 mg twice for ten days or a corresponding placebo starting directly after randomization (day 1), treatment with fluvoxamine decreased the hospitalization need in high-risk outpatients with early diagnosed COVID-19. Thus, such trials during the pandemic surged the market growth and are expected to continue the upward trend over the forecast period due to increased awareness about mental health during the pandemic period.

The increasing number of cases of depression around the world, increasing awareness about depression, and the emergence of novel biologics are the significant factors driving the market growth. Depression mainly occurs due to the factors such as social isolation and stressful work environment, which contribute to increasing the number of people suffering from depression. It leads to increasing cases of suicide. The World Health Organization (WHO) data updated in September 2021 stated that depression is a prevalent mental illness, and according to estimates, around 5.0% of adults worldwide experience depression. Moreover, as per the same source, currently, the most significant cause of disability in the world is depression, which significantly contributes to the overall burden of the disease globally. Thus, such a high disease risk is creating demand for antidepressant use among the target population, thereby contributing to market growth.

Furthermore, in countries such as the UK and the US, characterized by their fast-paced economies, the percentage of the population affected by depression is high in every age group. For instance, according to the January 2022 data published by the Anxiety and Depression Foundation, generalized anxiety disorder affects 6.8 million adults annually or 3.1% of the US population. Thus, such a high prevalence is expected to drive the overall market growth over the forecast period.

However, the preference for non-pharmacological therapies over pharmacological ones and antidepressant drugs’ side effects and patent expiry is likely to hinder the market growth over the forecast period.

Antidepressant Market Trends

Major Depressive Disorder Segment is Expected to Witness Considerable Growth Over the Forecast Period

Major depressive disorder or depression’s possible causes comprise a combination of biological, psychological, and social sources of distress. The major risk factors include family history, significant life changes, certain medications, chronic health problems, and substance abuse. For treatment purposes, doctors generally prescribe antidepressants such as selective serotonin reuptake inhibitors (SSRIs).

The increasing number of cases of major depressive disorders across the globe is one of the significant factors propelling segment growth. For instance, as per the data published by WHO in September 2021, 5.7% of adults older than 60 years are suffering from depression, and approximately 280.0 million people globally have depression. Similarly, as per the January 2022 National Institute of Mental Health, an estimated 21.0 million adults in the US suffered from at least one major depressive episode. The number represented 8.4% of all US adults in 2020. Moreover, as per the January 2022 NCBI research article and as per Mordor Intelligence analysis, the prevalence of major depressive disorder (MDD) among the elderly is on the rise globally, and age and gender are few of the clinical and demographic variables that affect how often severe depression is among the elderly. Thus, the high burden of major depressive disorder globally is expected to surge the demand for antidepressants over the forecast period.

Moreover, the increasing recent developments related to the segment are also anticipated to drive the demand for antidepressants. For instance, in December 2021, Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on developing and commercializing therapeutics for central nervous system (CNS) disorders, received approval from the FDA for CAPLYTA (lumateperone) for the treatment of bipolar depression in adults. CAPLYTA is the only FDA-approved treatment for depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and adjunctive therapy with lithium or valproate. Such approvals for new products are anticipated to create new opportunities, thereby driving segment growth over the forecast period.

Therefore, the segment is expected to witness growth over the forecast period due to the abovementioned factors.

North America is Anticipated to Witness Significant Growth Over the Forecast Period

The increasing number of cases of depression is one of the major factors driving the overall growth of the antidepressant market in North America, particularly in the US, over the forecast period. Furthermore, the rise in the geriatric population and regional product launches are also expected to create more market opportunities. For instance, according to the 2021 Anxiety and Depression Association of America report, anxiety disorder is one of the most common mental illnesses in the US, affecting approximately 40 million American adults every year, which is 18.1% of the total population of the US. The same source also stated that more than 16.1 million American adults suffer from major depressive disorder yearly, which is more prevalent in women than men. Moreover, in May 2022, Pharmascience Canada, a division of Pharmascience Inc., launched its new generic drug, pms-LURASIDONE, in the Canadian market. Pms-LURASIDONE is a monotherapy for the management of the manifestations of schizophrenia in adults and adolescents (15-17 years of age). It is also helpful for acutely managing depressive episodes associated with bipolar disorder in adults and adolescents (13-17 years of age). Thus, the increasing prevalence of mental disorders and new product launches are expected to surge the demand for antidepressants, which in turn are further expected to drive the market in North America.

Key product launches, high concentration of market players or manufacturer’s presence, acquisitions and partnerships among significant players, and increasing cases of mental disorders in the US are some factors driving the growth of the antidepressant market in the country. For instance, the data updated by the National Institute of Mental Health (NIMH) in January 2022 shows depression is one of the most common mental health disorders in the US, and an estimated 46.9% of adolescents with a major depressive episode and significant impairment received treatment in the previous year. Furthermore, the growing approvals and increasing pipeline products by crucial players concentrated in the country are also driving the studied market. For instance, in February 2022, AbbVie submitted a supplemental New Drug Application (sNDA) for cariprazine (VRAYLAR) to the FDA for the adjunctive treatment of major depressive disorder (MDD) in patients who are receiving ongoing antidepressant therapy. Such developments are expected to drive market growth in the country.

Thus, given the factors above, the antidepressant market is expected to witness significant growth over the forecast period in North America.

Antidepressant Market Competitor Analysis

The market studied comprises a combination of multinational and domestic players. The entry barriers are comparatively less, and most drugs are available over the counter. The companies are actively involved in the global expansion of their product portfolio through partnerships, collaborations, and acquisitions. Some of the key players in the market are Allergan PLC, AstraZeneca, Eli Lilly and Company, GlaxoSmithKline PLC, H. Lundbeck AS, Johnson & Johnson, and Pfizer Inc., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
❖ レポートの目次 ❖

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Number of Cases of Depression Around the World
4.2.2 Increasing Awareness About Depression
4.2.3 Emergence of Novel Biologics
4.3 Market Restraints
4.3.1 Preference of Non-pharmacological Therapies over Pharmacological Therapies
4.3.2 Side Effects and Patent Expiry of Antidepressant Drugs
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value – USD Million)
5.1 Product
5.1.1 Selective Serotonin Reuptake Inhibitor (SSRI)
5.1.2 Serotonin-norepinephrine Reuptake Inhibitor (SNRI)
5.1.3 Tricyclic Antidepressant (TCA)
5.1.4 Monoamine Oxidase Inhibitor (MAOI)
5.1.5 Other Products
5.2 Depressive Disorder
5.2.1 Major Depressive Disorder
5.2.2 Obsessive-compulsive Disorder (OCD)
5.2.3 Generalized Anxiety Disorder (GAD)
5.2.4 Panic Disorder (PD)
5.2.5 Other Depressive Disorders
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbiVe Inc.
6.1.2 AstraZeneca
6.1.3 Eli Lilly and Company
6.1.4 GlaxoSmithKline PLC
6.1.5 Johnson & Johnson
6.1.6 H. Lundbeck AS
6.1.7 Merck & Co. Inc.
6.1.8 Pfizer Inc.
6.1.9 Sanofi
6.1.10 Sun Pharmaceuticals Pvt. Ltd
6.1.11 Dr. Reddy’s Laboratories

7 MARKET OPPORTUNITIES AND FUTURE TRENDS



★調査レポート[抗うつ薬のグローバル市場(2023~2028):選択的セロトニン再取り込み阻害薬(SSRI)、セロトニン・ノルアドレナリン再取り込み阻害薬(SNRI)、三環系抗うつ薬(TCA)、モノアミン酸化酵素阻害薬(MAOI)、その他] (コード:MOR23MH106)販売に関する免責事項を必ずご確認ください。
★調査レポート[抗うつ薬のグローバル市場(2023~2028):選択的セロトニン再取り込み阻害薬(SSRI)、セロトニン・ノルアドレナリン再取り込み阻害薬(SNRI)、三環系抗うつ薬(TCA)、モノアミン酸化酵素阻害薬(MAOI)、その他]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆